NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research Annual Meeting 2023

NEO Stock  USD 14.66  0.16  1.10%   
About 62% of all NeoGenomics' investors are looking to take a long position. The analysis of overall sentiment of trading NeoGenomics stock suggests that some investors are interested at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
FT. MYERS, FL ACCESSWIRE April 6, 2023 NeoGenomics, Inc. , a leading provider of oncology testing and global contract research services, announced today that the company and its coll

Read at accesswire.com
news
  

NeoGenomics Current Investor Sentiment

Panic Vs Confidence

62

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use NeoGenomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward NeoGenomics.

NeoGenomics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

NeoGenomics Historical Investor Sentiment

Investor biases related to NeoGenomics' public news can be used to forecast risks associated with an investment in NeoGenomics. The trend in average sentiment can be used to explain how an investor holding NeoGenomics can time the market purely based on public headlines and social activities around NeoGenomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
NeoGenomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for NeoGenomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average NeoGenomics news discussions. The higher the estimate score, the more favorable the investor's outlook on NeoGenomics.

NeoGenomics Maximum Pain Price Across March 21st 2025 Option Contracts

NeoGenomics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of NeoGenomics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of NeoGenomics' options.

NeoGenomics Fundamental Analysis

We analyze NeoGenomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earnings To Growth

Price To Earnings To Growth Comparative Analysis

NeoGenomics is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

NeoGenomics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeoGenomics stock to make a market-neutral strategy. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics with similar companies.

Peers

NeoGenomics Related Equities

GHGuardant Health   4.59   
0%
45.0%
MYGNMyriad Genetics   3.91   
0%
39.0%
TWSTTwist Bioscience   1.83   
0%
18.0%
NEOGNeogen   1.79   
0%
17.0%
SHCSotera Health   0.66   
0%
6.0%
CDNACaredx   0.43   
0%
4.0%
IQVIQVIA Holdings   0.28   
0%
2.0%
NTRANatera   0.06   
1.0%
0%
ICLRICON PLC   0.19   
1.0%
0%
MTDMettler Toledo   0.29   
2.0%
0%
CSTLCastle Biosciences   0.45   
4.0%
0%
CRLCharles River   0.81   
8.0%
0%
ACRSAclaris Therapeutics   1.92   
19.0%
0%
QGENQiagen NV   3.01   
30.0%
0%
BDSXBiodesix   10.00   
100.0%
0%
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.61)
Revenue Per Share
5.098
Quarterly Revenue Growth
0.104
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.